Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-10-15, Stock:LLY, The news for the past five days is as follows:
2019-10-08: NEWS1: UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report.NEWS2: Can We See Significant Institutional Ownership On The Eli Lilly and Company (NYSE:LLY) Share Register?.NEWS3: REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report.NEWS4: REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report.NEWS5: Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress.
2019-10-09: NEWS1: Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study.NEWS2: Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan.
2019-10-10: NEWS1: Here’s What Hedge Funds Think About Eli Lilly and Company (LLY).NEWS2: 3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates.NEWS3: J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector.NEWS4: Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study.
2019-10-11: NEWS1: Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval.NEWS2: UPDATE 1-Eli Lilly's migraine treatment wins U.S. FDA approval.NEWS3: Eli Lilly's migraine treatment wins U.S. FDA approval.NEWS4: Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals.NEWS5: Gilead-Galapagos Report Efficacy & Safety Results on RA Drug.NEWS6: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout.
2019-10-14: NEWS1: 52-Week Company Lows.NEWS2: Lilly Gets FDA Approval for New Oral Tablets for Migraine.NEWS3: Eli Lilly Stock Gets 2 Pieces of Good News.

Answer: Rise